Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo, Japan.
Cancer Sci. 2019 Jun;110(6):1853-1862. doi: 10.1111/cas.14023. Epub 2019 May 9.
The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. In this study, we aimed to identify novel biomarkers that reflect prognoses following chemoradiotherapy using tertiary lymphoid organs (TLO) expressed in the tumor microenvironment. Resected tumor specimens were obtained from 140 pancreatic cancer patients. We retrospectively investigated the clinical relevance of TLO by categorizing patients into those who underwent upfront surgery (surgery first [SF]) and those who received NAC. The immunological elements within TLO were analyzed by immunohistochemistry (IHC). In the IHC analysis, the proportions of CD8+ T lymphocytes, PNAd+ high endothelial venules, CD163+ macrophages and Ki-67+ cells within the TLO were higher in the NAC group than in the SF group. In contrast, the proportion of programmed cell death-1+ immunosuppressive lymphocytes within TLO was lower in the NAC group than in the SF group. The NAC group demonstrated favorable prognoses compared with the SF group. In the multivariate analysis, the TLO/tumor ratio was determined as an independent predictive prognostic factor. In conclusion, the administration of preoperative chemoradiotherapy may influence the immunological elements in the tumor microenvironment and result in favorable prognoses in pancreatic ductal adenocarcinoma patients.
术前新辅助放化疗(NAC)在预后极差的胰腺癌病例中的疗效已有报道。在这项研究中,我们旨在使用肿瘤微环境中表达的三级淋巴器官(TLO)来确定反映放化疗后预后的新型生物标志物。从 140 名胰腺癌患者中获得了切除的肿瘤标本。我们通过将患者分为直接手术(手术优先 [SF])组和接受 NAC 组,回顾性地研究了 TLO 的临床相关性。通过免疫组织化学(IHC)分析 TLO 内的免疫成分。在 IHC 分析中,NAC 组 TLO 内的 CD8+T 淋巴细胞、PNAd+高内皮静脉、CD163+巨噬细胞和 Ki-67+细胞的比例高于 SF 组。相比之下,NAC 组 TLO 内程序性细胞死亡-1+免疫抑制淋巴细胞的比例低于 SF 组。与 SF 组相比,NAC 组显示出更好的预后。在多变量分析中,TLO/肿瘤比被确定为独立的预测预后因素。总之,术前放化疗的应用可能会影响肿瘤微环境中的免疫成分,并导致胰腺导管腺癌患者的预后良好。